Research
Hormonal
The macrovascular benefits of GLP-1 receptor agonists should be prioritized over potential microvascular progression of DR.
Healthcare providers should weigh the cardiovascular benefits of GLP-1 receptor agonists against the risks of worsening DR.
StrongSupportsmedium confidence
Overall, the macrovascular reduction of cardiovascular and stroke risks from GLP-1 receptor agonists should be prioritized over the potential microvascular progression of DR.
Why this rating
Based on the context provided in the abstract.
Source
Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy
Anindya Samanta et al. · International Ophthalmology Clinics · 2024
DOI 10.1097/iio.0000000000000541
reviewCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →